Real life use of natalizumab and fingolimod in Austria: benefit-risk data from the Austrian Multiple Sclerosis Treatment Registry

M Guger, C Enzinger, F Leutmezer, Jörg Kraus, T Berger

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	English
Pages (from-to)	198-198
Journal	MULTIPLE SCLEROSIS
Volume	20
Publication status	Published - 2014
Event	Joint ACTRIMS-ECTRIMS Meeting - Boston, MA Duration: 10 Sept 2014 → 13 Sept 2014

Cite this

@article{766f8c31e8dd4c57a7a1cfea2678d7ad,

title = "Real life use of natalizumab and fingolimod in Austria: benefit-risk data from the Austrian Multiple Sclerosis Treatment Registry",

author = "M Guger and C Enzinger and F Leutmezer and J{\"o}rg Kraus and T Berger",

year = "2014",

language = "English",

volume = "20",

pages = "198--198",

journal = "MULTIPLE SCLEROSIS ",

issn = "1352-4585",

note = "Joint ACTRIMS-ECTRIMS Meeting ; Conference date: 10-09-2014 Through 13-09-2014",

}

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Real life use of natalizumab and fingolimod in Austria: benefit-risk data from the Austrian Multiple Sclerosis Treatment Registry

AU - Guger, M

AU - Enzinger, C

AU - Leutmezer, F

AU - Kraus, Jörg

AU - Berger, T

PY - 2014

Y1 - 2014

M3 - Abstract (Journal)

SN - 1352-4585

VL - 20

SP - 198

EP - 198

JO - MULTIPLE SCLEROSIS

JF - MULTIPLE SCLEROSIS

T2 - Joint ACTRIMS-ECTRIMS Meeting

Y2 - 10 September 2014 through 13 September 2014

ER -